Claire Lépinoux-Chambaud is a neuroscience researcher and co-founder of Innov’nCare. Prior to founding the company, she led the maturation program on the NFL-TBS.40-63 peptide at the Institut de Recherche et d’Ingénierie en Santé (IRIS), University of Angers, under the SATT Ouest Valorisation initiative. This program led to the creation of GlioCure, which she co-founded, continuing the development of the peptide for its anti-tumor activity.

During her doctoral research at the MINT laboratory, Claire conducted her thesis entitled “The NFL-TBS.40-63 Peptide Derived from Neurofilaments: Therapeutic Agent and Targeting Tool for Glioblastoma and Neural Stem Cells.” She is the first author of multiple scientific publications on this peptide and co-inventor of one of the three patent families protecting it.

Her doctoral work focused on the selectivity and cellular effects of the peptide across various cell types and animal models. She has thus developed specialized expertise in neuronal cytoskeleton biology, neural stem cells, and glioblastoma, along with strong skills in cellular and molecular biology, imaging, and animal experimentation.

Claire Lépinoux-Chambaud holds a PhD in Neurosciences from the University of Angers and a Master’s degree in Biology and Health from the University of Poitiers.

Clément Sanchez is a chemist and biologist and co-founder of Innov’nCare. He spent five years at GlioCure as a research engineer, working on the NFL-TBS.40-63 peptide. His responsibilities included organic synthesis, LC-MS analytical development, and 2D/3D cell culture, giving him comprehensive expertise from molecule design to preclinical evaluation.

Prior to that, Clément was a contract lecturer-researcher at the University of Cergy-Pontoise for three years, conducting research on the synthesis of amino acids and fluorescent peptides.

He completed his PhD on “Development of Intracellular Penetration Vectors for Targeting Cathepsin D Inhibitors”, which laid the foundation for his specialization in vectorization and targeted peptide design, bridging chemistry and biology.

Clément Sanchez holds a PhD in Molecular Engineering from the University of Montpellier and a Master’s degree in Chemistry from the University of Poitiers.

Carl Simonsson is a researcher in nanoformulation.

Dr. Carl Simonsson is a chemist specializing in the development and physicochemical characterization of colloidal systems and the vectorization of active ingredients. Since 2021, he has been the Head of Cure’nCaps, the formulation development service unit of the company Innov'nCare. Carl Simonsson has fifteen years of experience in the fields of formulation research, biopharmaceutics, and toxicology.

Before joining Cure’nCaps, he was an R&D project manager and head of formulation development at Carlina Technologies, a biopharmaceutical company specializing in the development of micro- and nanomedicines. In these roles, he managed formulation projects for proteins, peptides, and small therapeutic molecules for clients in the pharmaceutical industry.

Prior to that, he worked at the MINT laboratory (Translational Micro and Nanomedicines, INSERM 1066) on research projects in nanomedicine.

Carl Simonsson holds a PhD in Pharmaceutical Chemistry from the University of Gothenburg in Sweden.